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ABSTRACT
This paper describes the current knowledge of the
primary mode of action of a natural product,
ecteinascidin 743 (ET-743), derived from the marine
tunicate Ecteinascidia turbinata. ET-743 was initially
selected for preclinical development because of its
potent antitumor activity observed against several
human solid tumor types. In vitro, the drug is cytotoxic
in the nanomolar range, and in the case of some very
sensitive cell lines, in the picomolar range. The large
potency differences observed among several solid tumor
types indicate that this compound possesses some tumor
selectivity, but the molecular basis of these differential
effects remains to be elucidated. The present studies
were undertaken to evaluate the mechanism of action of
ET-743 in this context. The available information on
ET-743 binding to DNA and its effects on transcrip-
tional regulation point to a unique behavior of this drug,
as it independently affects specific gene transcription in
a promoter-dependent way. In addition, ET-743 shows
a peculiar pattern of selectivity in cells with different
defects in their DNA-repair pathways. These results
highlight a unique property of ET-743, possibly explain-
ing why it possesses antitumor activity against tumors
that are refractory to standard anticancer drugs, all of
which certainly act by mechanisms that are different
from that of ET-743. The Oncologist 2002;7:210-216
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INTRODUCTION
Although several alterations of mechanisms controlling
proliferation, differentiation, and cell death have been iden-
tified in many human neoplasms, we are still far from
understanding the key reactions to be blocked to cure can-
cer. Specific therapies able to hit relevant targets can be real-
istically developed for only a limited number of neoplastic
diseases. For this reason, it seems reasonable to explore
whether novel natural products discovered by empirical
approaches are effective against a variety of human cancers.
This paper focuses on a natural product of marine ori-



















Figure 1. Molecular structure of ecteinascidin 743 (ET-743).
Caribbean tunicate Ecteinascidia turbinata, as an example
of an effective novel drug [1-5] that can be considered the
prototype of a new class of anticancer compounds. ET-743
is currently in phase II clinical trials and has shown evi-
dence of activity in soft tissue sarcomas and in breast and
ovarian cancers [6-9]. The main body of information on the
mode of action of this drug is critically reviewed, particu-
larly in relation to the studies recently performed by our
laboratories.
BINDING TO DNA
Studies performed by Pommier et al. [10] at the
National Cancer Institute have demonstrated that ET-743
forms DNA adducts. These authors incubated, in vitro,
radiolabeled DNA fragments with ET-743, evaluated the
shift of electrophoretic migration, and analyzed the
sequence-specific binding by footprinting techniques.
These studies indicated that the ET-743-DNA adducts
involved the exocyclic N2 amino group of guanine located
in the DNA minor groove. This type of alkylation depends
on dehydration of the carbinolamine functional group of
ET-743 leading to the formation of an iminium intermedi-
ate which subsequently reacts with and causes binding 
to DNA.
Another important contribution to the understanding of
how ET-743 binds to DNA was made by Hurley and
coworkers. They reported a nuclear magnetic resonance
(NMR)-based model of ET-743 binding to duplex DNA
indicating that the A and B subunits of the drug are respon-
sible for DNA recognition and bonding, whereas the C sub-
unit does not have contact with DNA and protrudes out from
the minor groove [11, 12]. Gel shift assays combined with
high-field NMR have demonstrated that the alkylation of
ET-743 occurs at guanines located either in the sequence 5′-
PuGC-3′ or 5′-PyrGG-3′ [10-13]. Other adducts are formed,
but are less stable and are reversible [12-14], suggesting
that, after prolonged exposure, ET-743 would be released
from these less stable adducts and a progressively higher
percentage of ET-743 would be found bound to guanines
located in the frame of bases conferring high thermody-
namic stability. The reported structural changes induced by
ET-743, such as widening of the minor groove and bending
of DNA toward its major groove, could be important in
affecting the recognition and binding of transcription factors
or DNA-binding proteins (e.g., DNA repair proteins). The
changes in bending of DNA induced by ET-743 could be, in
some cases, incompatible with the binding of some tran-
scriptional factors, whereas, in other cases, bending could be
enhanced. The precise characterization of these effects
might explain why ET-743 simultaneously downregulates
some genes and upregulates others (see next section).
IN VITRO INTERFERENCE OF ET-743 WITH
DNA-BINDING PROTEINS AND TRANSCRIPTIONAL
REGULATION
The main structural differences between ET-743 and the
antibiotic saframycin, which does not possess antitumor
properties, is a tetrahydroisoquinolone C subunit, which is
absent in saframycin A. This observation prompted us to
speculate that this part of the molecule is crucial for the
mechanisms responsible for the antitumor activity.
According to the model proposed by Hurley and coworkers
[11, 12, 14], it seems that a C subunit not bound to DNA but
projecting out from the minor groove might be able to inter-
fere with DNA-binding factors. This hypothesis led us to
investigate whether transcription factors that bind to DNA
were inhibited by ET-743, which also binds to DNA [15].
We selected three types of factors: A) oncogene products,
such as MYC, c-MYB, and Maf; B) transcriptional activators
regulated during the cell cycle, such as E2F and SRF, and C)
general transcription factors, such as Sp1, TATA-binding
protein (TBP), and NF-Y. No inhibition of DNA binding was
found for Sp1, Maf, MYB, or MYC, while for TBP, E2F, and
SRF, inhibition was observed at concentrations higher than
50 µM. The inhibition of NF-Y binding was found to occur
at ET-743 concentrations in the range of 10-30 µM. Since
two subunits of NF-Y have a high analogy with histone 2B,
the effect of ET-743 on nucleosome reconstitution (i.e., a
chromatine-like fiber formed in vitro by adding histones to
DNA) was investigated, and it was found that a complete
inhibition occurred at drug concentrations of 3-10 µM. These
data would suggest that the mode of action correlates with
the ability of ET-743 to interfere with the binding of regula-
tory proteins to DNA, thus altering their specific function.
However, we have reported these data with caution since the
observed effect occurs at ET-743 concentrations that are
higher than 1 µM; whereas, the in vitro cytotoxic activity of
ET-743 consistently occurs in a much lower range of 10
picomolar to 10 nanomolar, at least two logs lower than the
concentrations used for the DNA binding studies.
Since these in vitro data indicated that one of the factors
that was preferentially affected by ET-743 was NF-Y, we
focused our attention on this factor, because NF-Y activates
the CCAAT element present in 25% of eukaryotic promot-
ers, including many promoters that regulate genes controlling
the cell cycle.
NIH-3T3 fibroblasts transfected with a reporter gene
under the control of HSP70 promoter, contain two CCAAT
boxes activated by NF-Y. In this system, it is possible to
demonstrate that a short treatment with ET-743 in the nM
range inhibits the induction of transcription of HSP70 [16].
This promoter-dependent effect was also seen by others for
the MDR1 gene [17], which contains NF-Y binding sites.
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A recent study indicates that several genes are either
down- or upregulated [18] in intestinal carcinoma HCT116
and breast MDA-MB-435 cell lines exposed to ET-743. It is
important to realize that not all genes are transcriptionally reg-
ulated by NF-Y, thus indicating that other mechanisms must
be involved in the transcriptional effects caused by ET-743.
The authors of this report have also found that a synthetic ana-
log of ET-743, phthalascidin (Pt650), causes similar effects
on gene expression to those caused by ET-743 [18].
Synold et al. [19] recently reported that the orphan
nuclear receptor, SXR, coordinately regulates drug metab-
olism through the induction of transcription of the gene
encoding for the cytochrome P450 enzyme, CYP3A4, as
well as the transcription of MDR1, a gene encoding Pgp, a
glycoprotein that regulates the efflux of several compounds
including several anticancer drugs. They found that many
xenobiotics, including drugs such as taxol, activate SXR,
thus enhancing both drug metabolism and its Pgp-mediated
drug clearance. ET-743 was found to be able to inhibit SXR
and consequently suppressed MDR1 gene transcription. The
inhibition of SXR, which appears to have several detoxifi-
cation genes as targets, might be relevant in relation to the
toxicity of ET-743 and of other drugs combined with ET-
743. The interesting paper by Synold et al. [19] has shown a
mechanism occurring in vitro. Further studies should be per-
formed to evaluate the relevance of SXR inhibition in well-
characterized cellular systems and in vivo to evaluate
whether therapeutic doses of ET-743 correlate with the inhi-
bition of SXR and to investigate any implications to the
pharmacological and toxicological properties of ET-743.
Takebayashi et al. reported that topoisomerase I was the
target of ET-743 [20] resulting in the formation of DNA
breaks. This evidence is not very convincing, as the experi-
ments were performed by treating tumor cells with 10 µM
ET-743, a concentration 500- to 1,000-fold higher than opti-
mal 50% inhibitory concentration values. As pointed out by
Martinez at al. [21], who synthesized ET-743 and other
related molecules, topoisomerase I cannot be the primary
target, considering that DNA topoisomerase I cross-links are
demonstrated only at concentrations several logs greater
than the cytotoxic ones. More recently, we provided more
definitive evidence that topoisomerase I cannot be the pri-
mary target of ET-743, since the drug is equally active in
wild-type yeast and in yeast with a deletion in the DNA
topoisomerase I gene [22]. The same researchers who sug-
gested that topoisomerase I was the target of ET-743, when
performing comparative experiments on camptothecin-
resistant mouse leukemia P388/CPT45 cells and on the par-
ent p388 cells, realized that they have similar sensitivity,
and thus, proposed that the cytotoxicity was independent of
topoisomerase I expression [23].
REPAIR MECHANISMS OF ET-743-INDUCED DNA
DAMAGE
To our knowledge, no data are available on the repair of
ET-743-induced DNA lesions in mammalian cells. To shed
some light on this point, we have investigated ET-743 cyto-
toxicity in cell lines with specific defects in DNA repair
mechanisms: mismatch repair, nucleotide excision repair,
and DNA-dependent protein kinase activity [22, 24]. Cell
lines with functional impairment of mismatch repair
(MMR), which are resistant to cisplatin, were as sensitive to
ET-743 as cell lines that are MMR proficient. ET-743 was
found to be about fivefold more active in cells lacking the
catalytic subunit of DNA-dependent protein kinase (DNA-
PK) and treatment with wortmannin, a potent inhibitor of
DNA-PK [22], sensitized the cells to ET-743.
A very unique response was observed in cells deficient in
nucleotide excision repair (NER). ET-743 did show decreased
cytotoxic activity in NER-deficient cell lines compared with
NER-proficient cell lines [22, 25]. Although the precise
mechanism by which NER-deficient cells become less sensi-
tive is not well understood, these findings further highlight the
peculiar and unique interaction between ET-743 and DNA.
To our knowledge, all known DNA-interacting drugs are, in
fact, either more effective or equally effective in NER-defi-
cient cells as in NER-proficient cells. As an example, in Table
1, ET-743 and cisplatin exhibited opposing patterns of sensi-
tivity in ERCC1-deficient cells and in transfected cells in
which the human ERCC1 gene had been inserted. Recently
these findings were confirmed by other laboratories in differ-
ent systems [13, 25]. Table 2 highlights the different patterns
of sensitivity to ET-743, cisplatin, and UV light in cells with
defined DNA repair defects.
An interesting study, recently published by Zewail-Foote
et al. [13], showed that not all ET-743-DNA adducts are
equally incised by Uvr ABC. The ET-743 adducts at the non-
preferred sequences (e.g. 5′-AGC and 5′-TGC) (see section
on DNA binding) were incised with the highest efficiency,
whereas adducts at the preferred sequences (5′-AGC and 
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Table 1. Cytotoxicity of DDP and ET-743 in NER proficient and
NER deficient cell lines
AA8 UV96 ERA5
DDP (µM) 27.2 0.47 11.6
ET-743 (nM) 0.59 >4 0.9
Shown are the 50% inhibitory concentrations of cisplatin (DDP)
and ET-743 in a Chinese hamster ovary parental cell line (AA8),
an ERCC1-deficient cell line (UV96), and a UV96 ERCC1-com-
plemented cell line (ERA5). Values are the mean of two experi-
ments done in quintuplicate. Standard error is not shown, being
less than 10%.
5′-TGC) were incised to a lesser extent. These authors pro-
posed that the adducts that are not efficiently repaired trap
DNA-nucleotide excision repair proteins forming cyto-
toxic complexes. This interesting hypothesis, if verified,
could have important implications for use with other DNA-
damaging agents in combinations with ET-743, including
radiation.
CELL CYCLE PERTURBATIONS AND PHASE
SPECIFICITY
The effects of 1 hour of ET-743 exposure, evaluated by
a BrdUrd/DNA biparametric flow-cytometric analysis,
showed that cells in the S phase during drug treatment pro-
gressed through this phase of the cell cycle more slowly
than control cells [26]. Also, cells that were in the G1 phase
progressed through the S phase slowly. At 24 hours, a high
percentage of ET-743-treated cells were arrested in the G2
phase, and only 120 or 168 hours afterwards, depending 
on the cell line, progressed to mitosis and restarted a new
cell cycle.
By synchronizing colon cancer SW620 cells by elutria-
tion, the sensitivity to ET-743 was comparatively evaluated
in cells in G1 S, and G2-M phases. The results showed that
the highest sensitivity to the drug occurred when cells were
in G1, and the lowest occurred when cells were in G2-M
phase. This finding is of interest, as the majority of avail-
able anticancer drugs that interact with DNA are preferen-
tially effective in S-phase cells, thus indicating a biological
effect of ET-743 that is distinct from those observed for the
other drugs.
Erba et al. [26] showed that ET-743 induces a signifi-
cant increase in p53 levels, which promotes apoptosis in cell
lines expressing wild-type p53. However, p53 status does
not appear to be relevant to the sensitivity to ET-743, as
cytotoxic activity does not correlate with the p53 status 
of different cell lines [24, 26], and the cytotoxicity is not
significantly different in p53 (-/-) or (+/+) mouse embryo
fibroblasts or in A2780 ovarian cancer cells or cells from the
A2780/CX3 subline transfected with a dominant-negative
mutant TP53 [26].
Unpublished data by this laboratory (Vikhanskaya,
unpublished observation) indicate that isogenic cell lines
expressing different levels of p73 exhibit a similar sensitivity
to ET-743, although a decrease in the sensitivity to cisplatin
was found in cell lines overexpressing p73 [27].
COMBINATION OF ET-743 WITH OTHER DRUGS
Considering the profound mechanistic differences
between ET-743 and other anticancer drugs, it was logical
to try to evaluate ET-743-based combinations. Preclinical
data indicate a synergy between ET-743 and anthracy-
clines, taxanes, and cisplatin. What is of particular interest
is the potentiation of activity of antitumor drugs with ET-
743 concentrations that alone produced moderate or no
antitumor effects. An example of this observation is shown
in Figure 2. ET-743 alone, at the concentration of 0.25 nM
for 24 hours, did not cause any detectable growth inhibi-
tion, but enhanced significantly the cytotoxicity of cis-
platin. This finding means that ET-743 may be used at
lower, relatively nontoxic, doses to potentiate the antitumor
activity of cisplatin. Ongoing in vivo studies in xenografts
appear to confirm that cisplatin efficacy can be increased
dramatically by the concomitant use of ET-743, even at
doses that alone produce no apparent effect [28].
Sequence-dependent synergies have also been observed
when combining ET-743 with doxorubicin or with paclitaxel
in soft tissue sarcoma cell lines [29]. The most favorable
effects were seen by treating the cells with ET-743 first fol-
lowed by doxorubicin, and by exposing the cells to paclitaxel
followed by ET-743.
CLINICAL INVESTIGATION
The phase I program with ET-743 in adult patients has
included six phase I trials investigating different schedules
[7, 9, 30-32]. Dose-limiting toxicities were hematological
toxicities and rhabdomyolysis. At the recommended dose,
reversible and noncumulative transaminitis was noted in
most of the patients. Evidence of objective activity,
including long-lasting responses, was noted in melanoma,
breast cancer, ovarian cancer, mesothelioma, and sar-
coma. Among 20 patients with advanced pretreated sar-
coma entered into different phase I trials at the
recommended dose or at the maximal tolerated dose, one
had a complete response, three had partial responses, and
two had minor responses, establishing a solid foundation
to further investigate the activity of ET-743 in connective
tissue tumors.
ET-743 is under active phase II/III development in dif-
ferent tumor types. The phase II data available suggest 
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Table 2. Unique spectrum of activity of ET-743 in cell lines with well-defined
DNA repair deficiencies




DDP ↓ ↑↑↑↑ ↑↑
ET-743 ↑ / – ↓↓↓↓ ↑↑
Abbreviations: ATM = ataxia telengectasia-mutated; DDP = cisplatin; DNA-PK
= DNA-dependent protein kinase; ET-743 = ecteinascidin 743.
a therapeutic benefit in patients with advanced soft tissue
sarcoma resistant to or relapsed subsequent to doxorubicin-
containing chemotherapy [33-35], with long-lasting
responses (median duration = 17 months). Also, prelimi-
nary evidence of activity in heavily pretreated advanced
breast cancer and in patients with advanced ovarian can-
cer resistant to or relapsed subsequent to platinum com-
plexes and paclitaxel is being generated [36, 37]. The
available results of phase II studies are summarized in
Tables 3 and 4 for soft-tissue sarcoma and epithelial breast
and ovarian cancer, respectively.
CONCLUSIONS
We have summarized some of the important molecular
mechanisms of action of the natural product ET-743, par-
ticularly related to its binding to DNA and its effect on
DNA repair and transcriptional regulation. We believe that
both the effects on transcription and on the DNA repair
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Figure 2. Cytotoxic effect of 24-
hour exposure with ecteinascidin
743 (ET-743) alone, cisplatin
(DDP) alone, or ET-743 and
DDP in combination evaluated
after 7 days by sulforhodamine B
test. Mean values of 7-10 repli-
cates and standard error (SE) are
reported. When SE is not reported,
it was less than 1% of the mean
value. ET-743 at the concentration
of 0.25 nM produced no
detectable inhibition of growth,
whereas it potentiated the cyto-
toxicity of DDP in a highly 















Table 3. Summary of phase II data with ET-743 in advanced soft tissue sarcoma (STS)
Investigators Tumor type Setting n of patients CR PR MR Median survival
Demetri et al. [34] STS* 1 line 34 2 3 3 19 months
Demetri et al. [34] STS 2/3 line 36 1 2 2 12.1 months
Yovine et al. [33] STS 2/3 >3 54 – 2 2 13 months
Le Cesne et al. [35] STS 2/3 line 99 – 9 7 9.11 months
1.5 mg/m2 i.v. 24-hour infusion on day 1 every 3-4 weeks.
Abbreviations: ET-743 = ecteinascidin 743; CR = complete response; PR = partial response; MR = minor response.
Table 4. Summary of phase II data with ET-743 in advanced pretreated ovarian and breast cancer
Investigators Tumor type Setting n of patients CR PR MR Comments
Zelek et al. [36] Breasta 2/3/4 line 22b – 4 2 Two patients had partial response of soft 
tissue disease with SD in bone metastases.
Median survival = 10 monthsc
Curigliano et al. [37] Ovariand 2 line 17 1 3 2 Activity in liver metastases
aET-743 dosage: 1.5 mg/m2 i.v. as a 24-hour infusion every 3-4 weeks.
b27 patients entered/22 with measurable disease.
cIntention-to-treat analysis.
dET-743 dosage: 1.3-1.6 mg/m2 i.v. as a 3-hour infusion every 3-4 weeks.
Abbreviations: ET-743 = ecteinascidin 743; CR = complete response; PR = partial response; MR = minor response; SD = stable disease.
mechanisms require further evaluation. At this stage, it is
still unclear why different promoters are differentially
affected, although an initial evaluation of the regulatory
DNA sequences tends to exclude that effects are related to
a specific DNA sequence. Whether the effects of ET-743
on transcription regulation are connected to NER pathways
is still not clear. It may be the case that the antitumor activ-
ity of ET-743 is defined by its effect on transcriptional reg-
ulation, and that optimal biological activity is achieved with
intact NER pathways, but it is uncertain whether intact
NER is required for activity. In spite of its as yet undeter-
mined mode of action, there is strong biological and bio-
chemical evidence that the mechanism of action of ET-743
is distinct from those previously described for other anti-
cancer drugs. Also, the relatively high cytotoxicity of ET-
743 against cells in G1 is a unique feature for a DNA
binding drug. The peculiar mechanism of action and the
observed biological properties of ET-743 in preclinical sys-
tems may help to explain why the ongoing clinical investi-
gations are reporting that this compound can be effective
against tumors that are relapsed or refractory to the avail-
able anticancer drugs [6-9].
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